Sign In
Buy SLS
$8.23
-0.81 (-8.96%)
At Close: Jun 05, 2026
SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)
01:12am, Tuesday, 24'th Feb 2026
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS - Get Free Report) saw some unusual options trading activity on Monday. Investors purchased 42,324 call options on the stock. This is an increase of appro
Solaris Resources (TSE:SLS) Reaches New 52-Week High – Should You Buy?
05:08am, Sunday, 25'th Jan 2026
Solaris Resources Inc. (TSE: SLS - Get Free Report)'s share price reached a new 52-week high during trading on Friday. The stock traded as high as C$13.12 and last traded at C$12.97, with a volume of
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
08:30am, Wednesday, 14'th Jan 2026
NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the developmen
SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)
02:34am, Saturday, 03'rd Jan 2026
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS - Get Free Report) saw unusually large options trading on Friday. Traders bought 149,934 call options on the company. This is an increase of approximately
SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up – What’s Next?
03:16am, Friday, 02'nd Jan 2026
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS - Get Free Report)'s share price gapped up before the market opened on Wednesday. The stock had previously closed at $3.31, but opened at $3.46. SELLAS Li
SELLAS Life Sciences Stock Is Surging Higher: What's Going On?
03:40pm, Monday, 29'th Dec 2025
SELLAS Life Sciences Group climbs higher after a premarket drop, reversing course as investors seem to react to new trial‑related updates.
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
08:35am, Monday, 29'th Dec 2025
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the developmen
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
06:00am, Wednesday, 24'th Dec 2025
VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - The U. S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], dri
NEW YORK, Dec. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the developmen
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
12:20pm, Thursday, 04'th Dec 2025
/PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells
Stock Traders Purchase High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)
01:12am, Wednesday, 19'th Nov 2025
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS - Get Free Report) saw unusually large options trading activity on Tuesday. Stock investors acquired 15,545 call options on the company. This is an increa
SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript
05:36pm, Wednesday, 29'th Oct 2025
SELLAS Life Sciences Group, Inc. ( SLS ) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs October 29, 2025 10:00 AM EDT Company Participants Angelos Stergiou - Founder, Pre
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the developme
BlackRock just bought this stock with full voting control
07:28am, Saturday, 18'th Oct 2025
The world's largest investment management firm, BlackRock (NYSE: BLK), has disclosed a 5.4% ownership stake in biopharmaceutical company Sellas Life Sciences Group (NASDAQ: SLS).
Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026
09:18pm, Tuesday, 19'th Aug 2025
SELLAS Life Sciences is developing GPS as a WT1 immunotherapy, which is in Phase 3 for AML. However, I believe their SLS009 candidate as a CDK9 inhibitor further gives the stock broad AML applicabilit
